Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics – a developer of in vivo cell therapies – for $1.5 billion in cash. Cambridge, Massachusetts-based Orbital is ...
Sanofi is reported to be preparing a move to take control of US biotech Ocular Therapeutix, after an initial bid was rejected last year. That is according to French newspaper La Lettre, which said ...
OCUL is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of OCUL shares has increased $0.96 since the market last closed. This is a 10.84% ...
OCUL is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of OCUL shares has decreased $0.28 since the market last closed. This is a 2.85% ...
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes ...
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes ...
Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results